Friday, February 2, 2007
Adult Stem Cell Biotech and Industry
One of the most famous companies is Osiris Therapeutics Inc.
The above chart shows you that the stock price of Osiris Therapeutics has been doubled since its IPO (inital public offering) on Aug 4, 2006, from about $10 to more than $20 a share. This happened only in less than 6 months! Don't you think stem cell biotech is a good investment opportunity?
Osiris Therapeutics has three products in clinical trials:
- Prochymal™ is finishing phase III of clinical trials for the treatment of steroid-refractory acute Graft vs. Host Disease (GVHD). This disease affects half of all patients who receive a bone marrow transplant for anemia and other diseases, and attacks the gastrointestinal tract, skin and liver. The same drug is also on phase II of clinical trials for the treatment of Crohn's disease, a painful inflammatory bowel disease which can lead to disability and surgery.
- Provacel™ is currently in early stages of clinical trials for the treatment of heart muscle damage in patients who have suffered a heart attack.
- Chondrogen™ is currently being evaluated in clinical trials for regeneration of the meniscus in the knee, and prevention of osteoarthritis.
Source: CNN money
Investing in Stem Cell Stocks
Subscribe to Post Comments [Atom]
Subscribe to Posts [Atom]